Suppr超能文献

磷霉素用于治疗耐药性尿路感染:一种未被充分探索的老药的潜力

Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.

作者信息

Patwardhan Vrushali, Singh Sarman

机构信息

, New Delhi, India.

出版信息

Int Urol Nephrol. 2017 Sep;49(9):1637-1643. doi: 10.1007/s11255-017-1627-6. Epub 2017 Jun 14.

Abstract

INTRODUCTION

Increased emergence of bacterial resistance and the limited options of novel antimicrobial agents have necessitated the reintroduction of some old antimicrobial agents. One such drug is fosfomycin, but its potential has not been explored fully, especially in India.

AIMS AND OBJECTIVES

To analyze the in vitro activity of fosfomycin, against the urinary isolates and to compare it with in vitro activity of other orally administered antimicrobial agents.

MATERIALS AND METHODS

This was a prospective observational study conducted between July 2014 and June 2016. All consecutive, non-duplicate and clinically significant urinary isolates obtained from patients of all ages and both genders, diagnosed to have UTI, were included. Patients already on antibiotic therapy were excluded. Urine culture was performed by semiquantitative method on cysteine lactose electrolyte-deficient medium and the isolates obtained in significant count were subjected to antimicrobial sensitivity testing by the Kirby Bauer disk diffusion method as per CLSI guidelines.

RESULTS

A total of 3947 non-repeating urinary isolates were included in the study, of which 2684 (68%) isolates originated from adult outpatients and remaining 1236 (32%) isolates from pediatric patients. Of these 2783 isolates were from enterobacteriaceae family. Out of these 2730 (98.1%) were sensitive to fosfomycin. Most [375 of 385 (97.4%)] Pseudomonas spp were also susceptible to fosfomycin. A majority of ESBL- (96.5%) and MBL (91.9%)-producing isolates were also susceptible to fosfomycin and so were of Gram-positive isolates [698/707 (96%)] and MRSA [61/69 (88.4%)] were susceptible to fosfomycin.

CONCLUSIONS

Fosfomycin showed an excellent in vitro activity against all urinary pathogens, including the Gram-positive or Gram-negative, ESBL and MBL producers. Fosfomycin should be considered as a highly effective alternative in treatment UTIs in both adults and pediatric patients.

摘要

引言

细菌耐药性的不断增加以及新型抗菌药物选择的有限性,使得一些旧的抗菌药物有必要重新启用。磷霉素就是这样一种药物,但其潜力尚未得到充分探索,尤其是在印度。

目的

分析磷霉素对尿液分离株的体外活性,并将其与其他口服抗菌药物的体外活性进行比较。

材料与方法

这是一项于2014年7月至2016年6月进行的前瞻性观察研究。纳入所有从各年龄段和性别的尿路感染患者中获得的连续、非重复且具有临床意义的尿液分离株。已接受抗生素治疗的患者被排除。采用半定量方法在半胱氨酸乳糖电解质缺乏培养基上进行尿液培养,对培养出的具有显著菌数的分离株,按照美国临床和实验室标准协会(CLSI)指南,采用 Kirby Bauer 纸片扩散法进行抗菌药敏试验。

结果

本研究共纳入3947株非重复尿液分离株,其中2684株(68%)分离株来自成年门诊患者,其余1236株(32%)分离株来自儿科患者。这些分离株中有2783株来自肠杆菌科。其中2730株(98.1%)对磷霉素敏感。大多数[385株中的375株(97.4%)]假单胞菌属菌株也对磷霉素敏感。大多数产超广谱β-内酰胺酶(ESBL)(96.5%)和产金属β-内酰胺酶(MBL)(91.9%)的分离株也对磷霉素敏感,革兰氏阳性分离株[698/707(96%)]和耐甲氧西林金黄色葡萄球菌(MRSA)[61/69(88.4%)]也对磷霉素敏感。

结论

磷霉素对所有尿液病原体,包括革兰氏阳性或革兰氏阴性、产ESBL和产MBL的病原体,均显示出优异的体外活性。在治疗成人和儿科患者的尿路感染时,磷霉素应被视为一种高效的替代药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验